RDUS Radius Health Inc.

Radius Health Strengthens Senior Management Team with Appointment of Chhaya Shah as Senior Vice President of Technical Operations

Radius Health Strengthens Senior Management Team with Appointment of Chhaya Shah as Senior Vice President of Technical Operations

WALTHAM, Mass., July 16, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq:RDUS) today announced the appointment of Chhaya Shah as Senior Vice President of Technical Operations.

"Ms. Shah will help strengthen and expand our technical operations infrastructure, optimize our supply chain and ramp-up our manufacturing capabilities, supporting the development of our late-stage clinical pipeline to commercial readiness. Chhaya's more than 25 years of industry experience in supply chain, quality assurance, and manufacturing will be critical in guiding Radius through our operational and commercial transformation as we make significant progress with our two lead clinical assets, abaloparatide-patch and elacestrant,” said Jesper Høiland, President and Chief Executive Officer of Radius.

Ms. Shah joins Radius from Synergy Pharmaceuticals where she was the Senior Vice President of Manufacturing and Technical Operations and helped successfully launch their first commercial product. Prior to Synergy, Chhaya served various functions at Shire Pharmaceuticals, in which she was responsible for end-to-end supply chain for over 20 products, developed quality systems and supported global approval of multiple products, including pre-approval regulatory inspections. Before joining Shire, Chhaya held various compliance, quality assurance and manufacturing leadership roles at Wyeth Pharmaceuticals, Vaccine Division and Abbott Laboratories.

About Radius

Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. For more information, please visit .

Investor Relations Contact:

Elhan Webb, CFA

Email:  

Phone: 617-551-4011

EN
16/07/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Radius Health Inc.

Radius Recycling Inc: 1 director

A director at Radius Recycling Inc sold 17,675 shares at 17.080USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...

 PRESS RELEASE

Gurnet Point Capital and Patient Square Capital Complete Their Acquisi...

Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc. CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Gurnet Point Capital (“Gurnet Point”) and Patient Square Capital (“Patient Square”) announced today the completion of their acquisition of Radius Health, Inc. (Nasdaq: RDUS) (“Radius”). Radius is a global, commercial-stage biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health and neuro-orphan diseases. Radius’ lead product, TYMLOS® (abaloparatide) was launched in the U.S. in 2017 for the treatment of...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Radius Health Announces Agreement to be Acquired by Gurnet Point Capit...

Radius Health Announces Agreement to be Acquired by Gurnet Point Capital and Patient Square Capital Transaction delivers immediate value and liquidity to Radius shareholdersResult of nine-month strategic review process by the Radius Board to maximize shareholder valuePotential per share value of $11.00, including $10.00 cash paid at closing and potential $1.00 CVRRepresents total transaction consideration of up to approximately $890 million BOSTON and CAMBRIDGE, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today announced tha...

 PRESS RELEASE

Menarini Group and Radius Health Submit New Drug Application to the U....

Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patientsPriority Review requested; if accepted, anticipate an 8-month FDA reviewPositive EMERALD study data previously announced on October 20, 2021First, and currently only, investigational oral SERD with positive topline resultsAdditional data presented at SABCS (December 2021) and ASCO (June 2022)Plan to file marketing authorization application for elacestrant in the EU in 2H 2022 FLORENCE, Italy and BOSTON, June ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch